A federal judge invalidated patents for market leader Amgen Inc.’s cholesterol drug Repatha, overturning a jury verdict and clearing Sanofi and Regeneron Pharmaceuticals Inc. to continue selling their competing Praluent.
A Delaware jury in February upheld the validity of two Amgen patents on Repatha. U.S. District Judge Richard Andrews had been expected to issue a decision on Amgen’s request to order the competing Praluent pulled from U.S. shelves, but his ruling on Aug. 28 tossing the verdict renders that moot.
The two Amgen patents, which were due to expire in August 2028, are related to antibodies called PCSK9 inhibitors, which ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.